How can manufacturing play in to the growth of the biologics industry in India? It's already one of Pharma's big hubs for manufacturing as it has such as cost effective rate to provide medication. The country needs $10 billion in exports and should continue to grow. By 2025, this number could skyrocket and Shaw sees new tax incentives from the government as a large part of that including elimination of service tax on manufacturing services provided to international clients, interest subsidies and long-term loans will also give the industry a much-needed boost.
The investment required to create biologics is something that India needs to move forward on. As the industry already has a significant stake in the production market, Shaw makes a significant point that investing and incentivising companies to expand and manufacture their products is an important part of future success in India.
Later this year at BioProcess International, we'll have a full track dedicated to the landscape of manufacturing. We'll hear from GlaxoSmithKline on how they are transforming biopharmaceutical manufacturing, Novartis Vaccines & Diagnostics on how they are planning to prepare for the future pipeline of the biomanufacturing and more. Find out more about these sessions and the rest of the program, download the agenda. If you'd like to join us this October 20-23, 2014 in Boston for these sessions, as a reader of this blog, when you register to join us and mention code BPI14JP, you'll save 20% off the standard rate! Have any questions or want to get involved? Reach out to Jennifer Pereira.
Do you see India growing as a hub for biologics manufacturing? If not, what do you see as the next manufacturing hub?
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment